AIM Immunotech Inc. annual report, FY2014

Business context and reporting period

This is Hemispherx Biopharma, Inc.’s Form 10-K for the fiscal year ended December 31, 2014, filed March 19, 2015. The request metadata names AIM Immunotech Inc.; the filing itself identifies Hemispherx, so verify the issuer and filing match. Hemispherx was a clinical-stage specialty pharmaceutical company developing Ampligen and Alferon products. Figures below are in U.S. dollars unless noted.

Key financial metrics

Revenue came from the FDA-authorized Ampligen open-label cost-recovery treatment program; the company reported no Alferon finished goods available for commercial sale. The filing does not provide a meaningful commercial gross margin. The accumulated deficit was $277.769 million at year-end.

Material changes versus the prior comparable period

• Net loss widened by $1.225 million, or about 8%, while revenue rose $47,000, or 31%.
• Research and development expense increased 8% to $8.988 million, mainly reflecting Alferon facility testing and development work; general and administrative expense rose 17% to $9.057 million, largely due to higher legal costs and executive compensation.
• Operating cash use fell by $2.912 million. The company raised $12.817 million net through its at-the-market equity program, versus $249,000 in 2013, issuing approximately 35.1 million shares.
• Cash, cash equivalents and marketable securities together declined about $2.086 million to $16.108 million. Marketable securities fell to $13.952 million from $17.391 million; the company recorded a $145,000 impairment loss, compared with $800,000 in 2013.
• Working capital declined by $3.949 million. The balance sheet reported no debt at year-end; the remaining capital-lease balance was $22,000, and redeemable warrants had expired.

Outlook, risks, contingencies and unusual items

• Ampligen: The FDA declined the CFS application in a February 2013 Complete Response Letter, citing the need for at least one additional clinical trial, nonclinical studies and data analyses, including further efficacy, safety and manufacturing work. Management estimated a new controlled study could take 18 months to three years after design acceptance, and said the work would exceed current financial resources without additional funding. No approval timetable or forecast of material product cash inflows was provided.
• Alferon: U.S. commercial sales had been halted since 2008 because finished inventory expired. The company wrote off remaining older inventory after it could not resolve FDA questions. New API production began in February 2015; commercial sales would require facility inspection, validation, and FDA release of acceptable product. Management anticipated, subject to approvals, commercial availability no earlier than the second half of 2015. This was a forward-looking expectation, not an assured date.
• Funding and dilution: The company stated it would likely need additional financing for development and commercialization. Its ATM remained a key funding source, but further share issuance could dilute existing holders; charter restrictions could also limit fundraising shares without stockholder approval. From January 1 through March 1, 2015, it sold about 14.5 million shares for $3.545 million net.
• Research and Ebola: The company reported encouraging laboratory findings for Ampligen and Alferon against Ebola, including preclinical reports received in late 2014 and a mouse study announced in February 2015. These findings do not establish human efficacy. The filing also described a positive EU orphan-drug opinion for Ampligen, with final designation still pending.
• Legal matters: The securities class action had a settlement agreement in principle, subject to court approval. Shareholder derivative cases and a former CFO’s employment-related suit remained unresolved; management said outcomes could not be predicted. The company recorded no gain or loss contingencies for the disclosed proceedings. It also won the Cato litigation and received a $770,853 fee award in January 2015, though collection and an appeal remained uncertain. A separate $188 million U.S. judgment against Johannesburg Consolidated Investments was not domesticated in South Africa; related bonds were forfeited and an approximately $200,000 fee award issued.
• Other notable items: The company sold New Jersey net operating losses for $1.126 million in 2014, a cash-generating item not representing product revenue. Executive performance bonuses and ATM-linked compensation were also material. Management reported effective disclosure controls and internal control over financial reporting, with no material weaknesses identified; the auditor gave an unmodified opinion on the financial statements.

Important facts for investors to verify

1. Confirm the issuer identity: the filing is for Hemispherx Biopharma, not AIM Immunotech Inc.
2. Check the current status of the Ampligen FDA response, required studies, funding needs and any regulatory submissions.
3. Verify whether Alferon manufacturing validation, FDA inspection and finished-product release occurred, and whether commercial sales resumed.
4. Review subsequent cash burn, liquidity, ATM share issuance and the effects of dilution and share-authorization limits.
5. Track court approval and terms of the securities-class-action settlement, the derivative and former-CFO cases, and the Cato appeal and fee recovery.
6. Distinguish preclinical Ebola and other laboratory results from evidence of safety or efficacy in human trials.